


Substitute for 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				COMPLETE IF KNOWN	
				Application Number	09/416,812
				Filing Date	10-13-1999
				First Named Inventor	Howe, J.
				Group Art Unit	1614
Examiner Name					
Sheet	1	of	8	Attorney Docket Number	CJ-0925K US


U.S. PATENT DOCUMENTS					
Examiner Initials	CITE NO	U.S. Patent Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD-YYYY)	Pages, Columns Lines Where Relevant Passages or Relevant Figures Appear
	AA	5,846,945	McCormick	12-08-1998	
	AB	5,801,029	McCormick	09-01-1998	
	AC	5,698,443	Henderson, et al.	12-16-1997	
	AD	5,677,178	McCormick	10-14-1997	
	AE	5,648,478	Henderson	07-15-1997	
	AF	5,856,181	McCormick	01-05-1999	

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns Lines Where Relevant Passags or Relevant Figures Appear	T
		Office	Number	Kind Code				
	FA	PCT	WO 93/19191	A1	Centre National De La Recherche Scientifique	09-30-1993		
	FB	CA	2,051,289	A1	General Hospital Corporation	03-15-1992		
	FC	PCT	WO 98/29555	A2	Onyx Pharmaceuticals	07-09-1998		
	FD	PCT	WO 96/25515	A1	Board of Regents, The University of Texas System	08-22-1996		
	FE	PCT	WO 97/01358	A1	Calydon	01-16-1997		
	FF	PCT	WO 96/30512	A1	Rhone-Poulenc Rorer S.A.	10-03-1996		
	FG	PCT	WO 98/53853	A1	Transgene	12-03-1998		
	FH	PCT	WO 95/19434	A1	Calydon	07-20-1995		
	FI	PCT	WO 98/21350	A1	Board of Regents, The University of Texas System	05-22-1998		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				COMPLETE IF KNOWN	
				Application Number	09/416,812
				Filing Date	10-13-1999
				First Named Inventor	Howe, J.
				Group Art Unit	1614
				Examiner Name	
Sheet	2	of	8	Attorney Docket Number	CJ-0925K US




OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author, (in CAPITAL LETTERS), title of the article (when appropriate, title of the item (book, magazine, journal, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/country where published.	T
	PA	Lusky, et al., (1998), In Vitro and In Vivo Biology of Recombinant Adenovirus Vectors with E1, E1/E2A, or E1/E4 Deleted, J. Virology Vol. 72, Pages 1-11	
	PB	Wilson, (1996), Adenoviruses as Gene-Delivery Vehicles, New England Journal of Medicine Vol 334,	
	PC	Fritz, (1996), Adenoviral Vectors for Gene Transfer	
	PD	Egan, et al., (1988), Mapping of Cellular Protein-Binding Sites on the Products of Early-Region 1A of Human Adenovirus Type 5, Mol. And Cellular Biology Vol. 8, Pages 3955-3959	
	PE	Howe, et al., (1990), Retinoblastoma growth suppressor and a 300-kDa protein appear to regulate cellular DNA synthesis, PNAS Vol. 87, Pages 5883-5887	
	PF	Bernstein, (1998), Have you used an adeno vector...lately?, Nature Genetics Vol. 18, Pages 305-306	
	PG	Ginsberg, et al., (1989), Role of early region 3 (E3) in pathogenesis of adenovirus disease, PNAS Vol. 86, Pages 3823-3827	
	PH	Steegen, et.al., (1998), The large E1B protein together with the E4orf6 protein target p53 for active degradation in adenovirus infected cells, Oncogene Vol.16, Pages 349-357	
	PI	Raper, et. al., (1998), Selective Gene Transfer into the Liver of Non-Human Primates with E1-Deleted, E2A-Defective, or E1-E4 Deleted Recombinant Adenoviruses, Human Gene Therapy Vol. 9, Pages 671-679	
	PJ	Russell, et al., (1998), Human gene targeting by viral vectors, Nature Genetics Vol. 18, Pages 325-330	
	PK	Vile, et. al., (1998), Strategies for achieving multiple layers of selectivity in gene therapy, Molecular Medicine Today, Pages 84-92	
	PL	Gemma, et.al., (1998) hSmad5 gene, a human hSmad family member: its full length cDNA, genomic structure, promoter region and mutation analysis in human tumors, Oncogene Vol. 16, Pages 951-956	
	PM	Bayley, et. al., (1994), Adenovirus E1A proteins and transformation (Review), Int'l Journal Oncology Vol. 5, Pages 425-444	
	PN	Deonarain, et.al., (1995), Genetic delivery of enzymes for cancer therapy, Gene Therapy Vol. 2, Pages 235-244	
	PO	Jelsma, et.al., (1989), Sequences in E1A Proteins of Human Adenovirus 5 Required for Cell Transformation, Repression of a Transcriptional Enhancer, and induction of Proliferating Cell Nuclear Antigen, Virology Vol. 171, Pages 120-130	
	PP	Whyte, et. al., (1989), Cellular Targets for Transformation by the Adenovirus E1A Proteins, Cell Vol. 56, Pages 67-75	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				COMPLETE IF KNOWN	
				Application Number	09/416,812
				Filing Date	10-13-1999
				First Named Inventor	Howe, J.
				Group Art Unit	1614
				Examiner Name	
Sheet	3	of	8	Attorney Docket Number	CJ-0925K US




OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author, (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/country where published.	T
	PQ	Howe, et. al., (1992), Effects of Ad5 E1A Mutant Viruses on the Cell Cycle in Relation to the Binding of Cellular Proteins Including the Retinoblastoma Protein and Cyclin A, Virology Vol. 186, Pages 15-24	
	PR	Horowitz, (1990), Adenoviridae and Their Replication, Virology, Pages 1679-1713	
	PS	Jones, et. al., (1979), An adenovirus type 5 early gene function regulates expression of other early viral genes, PNAS Vol. 76, No. 8, Pages 3665-3669	
	PT	Chang, et. al., (1995), Cytostatic Gene Therapy for Vascular Proliferative Disorders with a Constitutively Active Form of the Retinoblastoma Gene Product, Science Vol. 267, Pages 518-522	
	PU	Jelsma, et. al., (1988), Use of Deletion and Point Mutants Spanning the Coding Region of the Adenovirus 5 E1A Gene to Define a Domain That is Essential for Transcriptional Activation, Virology Vol. 2, Pages 494-502	
	PV	Kim, et. al., (1998) Requirement for Specific Proteases in Cancer Cell Intravasation as Revealed by a Novel Semiquantitative PCR-Based Assay, Cell Vol. 94, Pages 353-362	
	PW	Smith, et. al., (1994), Interaction of the p53-Regulated Protein Gadd45 with Proliferating Cell Nuclear Antigen, Science Vol. 266, Pages 1376-1379	
	PX	Hiyoshi, et. al., (1992), Clinicopathological Significance of Nuclear Accumulation of Tumor Suppressor Gene p53 Product in Primary Lung Cancer, Jpn. J. Cancer Res. Vol. 83, Pages 101-106	
	PY	Chen, et. al., (1991), Expression of wild-type p53 in human A673 cells suppresses tumorigenicity but not growth rate, Oncogene Vol. 6, Pages 1799-1805	
	PZ	Russ, et. al., (1996), Self-Deleting Retrovirus Vectors for Gene Therapy, Journal of Virology, Vol. 71 No. 4, Pages 3197-3207	
	QA	Lachmann, et. al., (1997), Utilization of the Herpes Simplex Virus Type 1 Latency-Associates Regulatory Region To Drive Stable Reporter Gene Expression in the Nervous System, Journal of Virology Vol. 70, No. 8, Pages 4927-4932	
	QB	Grodzicker, et. al., (1980), Expression of Unselected Adenovirus Genes in Human Cells Co-transformed with the HSV-1 tk Gene and Adenovirus 2 DNA, Cell Vol. 21, Pages 453-463	
	QC	Wersto, et. al., (1998), Recombinant, Replication-Defective Adenovirus Gene Transfer Vectors Induce Cell Cycle Dysregulation and Inappropriate Expression of Cyclin Proteins, Journal of Virology, Pages 9491-9502	
	QD	Roth, (1999), Snapshots of ARF1: Implications for Mechanisms of Activations and Inactivation, Cell Vol. 97 Pages 149-152	
	QE	Shenk, (1996), Adenoviridae: The Viruses and Their Replication, Fields Virology, Third Edition, Chapter 67, Fields et. al., (editors) Lippencott-Raven Publishers, Philadelphia, Pages 2111-2148	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


Substitute for 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				COMPLETE IF KNOWN	
				Application Number	09/416,812
				Filing Date	10-13-1999
				First Named Inventor	Howe, J.
				Group/Art Unit	1614
				Examiner Name	
Sheet	4	of	8	Attorney Docket Number	CJ-0925K US



OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author, (in CAPITAL LETTERS), title of the article (when appropriate, title of the item (book, magazine, journal, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/country where published.	T
	QF	FDA Agrees With Onyx's Phase III Trial Design for Onyx-015 In Head and Neck Cancer: PR News Wire via Dow Jones, 09-07-99	
	QG	Vile, et. al., (1994), Gene transfer technologies for the gene therapy of cancer, Gene Therapy Vol. 1, Pages 88-98	
	QH	Friedmann, (1992), A brief history of gene therapy, Nature Genetics Vol. 2, Pages 93-98	
	QI	Onyx Awarded Patent for Viral Cancer Therapy, PR Newswire, 4-28-99	
	QJ	Gluzman, (date unknown), Helper-free Adenovirus Type-5 Vectors, Journal unknown	
	QK	Newman, (1954), Virus Treatment in Advanced Cancer, Cancer Vol. 7, Pages 106-118	
	QL	Momand, et. al., (1992), The mdm-2 Oncogene Product Forms a Complex with the p53 Protein and Inhibits p53-Mediated Transactivation, Cell Vol. 7, Pages 1237-1245	
	QM	Mietz, et. al., (1992), The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein, EMBO Journal Vol. 11, No. 13, Pages 5013-5020	
	QN	Graham, et. al., (1991), Manipulation of Adenovirus Vectors, Methods in Molecular Biology Vol. 7, Pages 109-128	
	QO	Phelps, et. al., (1992), Structure-Function Analysis of the Human Papillomavirus Type 16 E7 Oncoprotein, Journal of Virology Vol. 66, No. 4, Pages 2418-2427	
	QP	Brokaw, et. al., (1994), A Mutational Analysis of the Amino Terminal Domain of the Human Papillomavirus Type 16 E7 Oncoprotein, Virology Vol. 205, Pages 603-607	
	QQ	Maxwell, et. al., (19896), Regulated Expression of a Diphtheria Toxin A-Chain Gene Transfected into Human Cells: Possible Strategy for Inducing Cancer Cell Suicide, Cancer Research Vol. 46, Pages 4660-4664	
	QR	Martuza, et. al., (1991), Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant, Science Vol. 252, Pages 854-856	
	QS	Whyte, et. al., (1989), Cellular Targets for Transformation by the Adenovirus E1A Proteins, Cell Vol. 56, Pages 67-75	
	QT	Cote, et. al., (1991), Genetic Alterations of the p53 Gene Are a Feature of Malignant Mesotheliomas, Cancer Research Vol. 51, Pages 5410-5416	
	QU	Maxwell, et. al., (1993), Binding of cellular proteins to a conformational domain of tumor suppressor protein p53, Oncogene Vol. 8, No. 12, Pages unknown	

Examiner Signature		Date Considered	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

Substitute for 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				COMPLETE IF KNOWN	
				Application Number	09/416,812
				Filing Date	10-13-1999
				First Named Inventor	Howe, J.
				Group Art Unit	1614
				Examiner Name	
Sheet	5	of	8	Attorney Docket Number	CJ-0925K US




OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.	Include name of the author, (in CAPITAL LETTERS), title of the article (when appropriate, title of the item (book, magazine, journal, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/country where published.	T	
	QV	Iwabuchi, et. al., (1994), Two cellular proteins that bind to wild-type but not mutant p53, PNAS Vol. 91, Pages 6098-6102		
	QW	Hamel, et. al., (1992), Transcriptional Repression of the E2-Containing Promoters EllaE, c-myc, and RB1 by the Product of the RB1 Gene		
	QX	Crook, et. al., (1991), Degradation of p53 Can Be Targeted by HPV E6 Sequences Distinct from Those Required for p53 Binding and Trans-Activation, Cell Vol. 67, Pages 547-556		
	QY	Takimoto, et. al., (1994), Identification of Cellular Proteins That Bind The Central Conserved Region of p53, Biochemical and Biophysical Research Communications Vol. 202, No. 1, Pages 490-496		
	QZ	Chen, et. al., (1994), Hot-Spot p53 Mutants Interact Specifically with Two Cellular Proteins during Progression of the Cell Cycle, Molecular and Cellular Biology Vol. 14, No. 10, Pages 6764-6772		
	RA	Barak, et. al., (1992), Enhanced binding of a 95 kDa protein to p53 in cells undergoing p53-mediated growth arrest, The EMBO Journal Vol. 11, No. 6, Pages 2115-2121		
	RB	Truant, et. al., (1993), Direct Interaction Between the Transcriptional Activation Domain of Human p53 and the TATA Box-binding Protein*, The Journal of Biological Chemistry Vol. 268, No. 4, Pages 2284-2287		
	RC	Velcich, et. al., (1988), Adenovirus E1a ras Cooperation Activity Is Separate from Its Positive and Negative Transcription Regulatory Functions, Molecular and Cellular Biology Vol. 8, No. 5, Pages 2177-2183		
	RD	Subramanian, et. al., (1995), p53-independent Apoptotic and Necrotic Cell Deaths Induced by Adenovirus Infection: Suppression by E1B 19K and bcl-2 Proteins ¹ , Cell Growth & Differentiation Vol. 6, Pages 131-137		
	RE	Barker, et. al., (1987), Adenovirus Proteins from Both E1B Reading Frames Are Required for Transformation of Rodent Cells by Viral Infection and DNA Transfection, Virology Vol. 156, Pages 107-121		
	RF	Mak, et. al., (1990), Separate Regions of an Adenovirus E1B Protein Critical for Different Biological Functions, Virology Vol. 176, Pages 553-562		
	RG	Horowitz, (1985), Adenoviral Diseases, Virology, Pages 477-495		
	RH	Bjorn, et. al., (1990), Selective Elimination of Breast Cancer Cells from Human Bone Marrow Using an Antibody-Pseudomonas Exotoxin A Conjugate, Cancer Research Vol. 50, Pages 5992-5996		
	RI	Shepherd, et. al., (1993), Induction of the Cell Cycle in Baby Rat Kidney Cells by Adenovirus Type 5 E1A in the Absence of E1B and a Possible Influence of p53, Journal of Virology Vol. 67, No. 5, Pages 2944-2949		
	RJ	Shingu, et. al., (1991), Therapeutic effects of bovine enterovirus infection on rabbits with experimentally induced adult T cell leukaemia, Journal of General Virology Vol. 72, Pages 2031-2034		
	RK	Smith, et. al., (1956), Studies on the use of viruses in the treatment of carcinoma of the cervix, Cancer Vol. 9, Pages 1212-1218		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


Substitute for 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				COMPLETE IF KNOWN	
				Application Number	09/416,812
				Filing Date	10-13-1999
				First Named Inventor	Howe, J.
				Group Art Unit	1614
Examiner Name					
Sheet	6	of	8	Attorney Docket Number CJ-0925K US	



OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author, (in CAPITAL LETTERS), title of the article (when appropriate, title of the item (book, magazine, journal, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/country where published.	T
	RL	Von Hoff, et. al., (1998), Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time, British Journal of Cancer Vol. 78, No. 3, Pages 9-13	
	RM	Barker, et. al., (1987), Adenovirus Proteins from Both E1B Reading Frames Are Required for Transformation of Rodent Cells by Viral Infection and DNA Transfection, Virology Vol. 156, Pages 107-121	
	RN	Bernards, et. al., (1986), Role of the Adenovirus Early Region 1B Tumor Antigens in Transformation and Lytic Infection, Virology Vol. 150, Pages 126-139	
	RO	Osborne, et. al., (1982), The TATA Homology and the mRNA 5' Untranslated Sequence Are Not Required for Expression of Essential Adenovirus E1A Functions, Cell Vol. 40, Pages 139-148	
	RP	Nevins, (1981), Mechanism of Activation of Early Viral Transcription by the Adenovirus E1A Gene Product, Cell Vol. 26, Pages 213-220	
	RQ	Curtois, et. al., (1984), Adenovirus E1A protein activation of an integrated viral gene, The EMBO Journal Vol. 3, No. 5, Pages 1145-1149	
	RS	Dion, et. al., (1996), E1A RNA transcripts amplify adenovirus-mediated tumor reduction, Gene Therapy Vol. 3, Pages 1021-1025	
	RT	Kim, et. al., (1998), ONYX-015: Clinical data are encouraging, Nature Medicine Vol. 4, No. 12, Pages 1341-1342	
	RU	Rothmann, et al., (1998), Replication of ONYX-015, a Potential Anticancer Adenovirus, Is Independent of p53 Status in Tumor Cells, Journal of Virology Vol. 72, No. 12, Pages 9470-9478	
	RV	Rittner, et. al., (1997), Conditional Repression of the E2 Transcription Unit in E1-E3-Deleted Adenovirus Vectors Is Correlated with a Strong Reduction in Viral DNA Replication and Late Gene Expression In Vitro, Journal of Virology Vol. 71, No. 4, Pages 3307-3311	
	RW	Heise, et. al., (1997), ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents, Nature Medicine Vol. 3, No. 6, Pages 639-645	
	RX	Hall, (1998), p53-dependent cell death/apoptosis is required for a productive adenovirus infection, Nature Medicine Vol. 4, No. 9, Pages 1068-1072	
	RY	Goodrum, (1998), p53 Status Does Not Determine Outcome of E1B 55-Kilodalton Mutant Adenovirus Lytic Infection, Journal of Virology Vol. 72, No. 12, Pages 9479-9490	
	RZ	Hall, (1998), p53-dependent cell death/apoptosis is required for a productive adenovirus infection, Nature Medicine Vol 4, No. 9, Pages 1068-1072	
	SA	Bischoff, et. al., (1996), An Adenovirus Mutant That Replicates Selectively in p53-Deficient Human Tumor Cells, Science Vol. 274, Pages 373-376	

Examiner Signature		Date Considered	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

Substitute for 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				COMPLETE IF KNOWN	
				Application Number	09/416,812
				Filing Date	10-13-1999
				First Named Inventor	Howe, J.
				Group Art Unit	1614
				Examiner Name	
Sheet	7	of	8	Attorney Docket Number	CJ-0925K US



OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author, (in CAPITAL LETTERS), title of the article (when appropriate, title of the item (book, magazine, journal, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/country where published.	T
	SB	Turnell, et. al., (1999), The Replicative Capacities of Large E1B-Null Group A and Group C Adenoviruses Are Independent of Host Cell p53 Status, Journal of Virology Vol. 73, No. 3, Pages 2074-2083	
	SC	Ridgway, et. al., (1997), p53/E1b58kDa Complex Regulates Adenovirus Replication, Virology Vol. 237, Pages 404-413	
	SD	Steegenga, et. al., (1998), The large E1B protein together with the E4orf6 protein target p53 for active degradation in adenovirus infected cells, Oncogene Vol. 16, Pages 349-357	
	SE	Hay, et. al., (1999), Targeting the Replication of Adenoviral Gene Therapy Vectors to Lung Cancer Cells: The Importance of the Adenoviral E1b-55kD Gene, Human Gene Therapy Vol. 10, Pages 579-590	
	SF	Querido, et. al., (1997), Regulation of p53 Levels by the E1B 55-Kilodalton Protein and E4orf6 in Adenovirus-Infected Cells, Journal of Virology Vol. 71, No. 5, Pages 3788-3798	
	SG	Herbst, et. al., (1988), Regulation of Adenovirus and Cellular Gene Expression and of Cellular Transformation by the E1B-Encoded 175-Amino-Acid Protein, Journal of Virology Vol. 62, No. 12, Pages 4634-4643	
	SH	Yew, et. al., (1990), Dissection of Functional Domains in the Adenovirus 2 Early 1B 55K Polypeptide by Suppressor-Linker Insertional Mutagenesis, Virology Vol. 179, Pages 795-805	
	SI	Subramanian, et. al., (1986), Separation of the Functions Controlled by Adenovirus 2/p+ Locus, Virology Vol. 150, Pages 381-389	
	SJ	Pilder, et. al., (1986), The Adenovirus E1B-55K Transforming Polypeptide Modulates Transport or Cytoplasmic Stabilization of Viral and Host Cell mRNAs, Molecular and Cellular Biology Vol. 6, No. 2, Pages 470-476	
	SK	Mak, et. al., (1990), Separate Regions of an Adenovirus E1B Protein Critical for Different Biological Functions, Virology Vol. 176, Pages 553-562	
	SL	Howe, (1992), Control of Gene Expression and Cell Cycle Regulation by Adenovirus 5 E1A Proteins, A Thesis Submitted to the School of Graduate Studies in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy, McMaster University	
	SM	Moore, (1954), Effects of Viruses on Tumors ¹ , Ann Rev Microbiol Vol. 8, Pages 393-410	
	SN	Orkin, et. al., (1995), Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy	
	SO	Jones, et. al., (1979), Isolation of Adenovirus Type 5 Host Range Deletion Mutant Defective for Transformation of Rat Embryo Cells, Cell Vol. 17, Pages 683-689	
	SP	Jones, et. al., (1978), Isolation of Deletion and Substitution Mutants of Adenovirus Type 5, Cell Vol. 13, Pages 181-188	

Examiner Signature		Date Considered	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

